Jounce Reports First Quarter 2017 Financial Results

CAMBRIDGE, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the first quarter ended March 31, 2017.

“Our successful IPO in the first quarter marked an important milestone for the company and has provided us the financial flexibility to focus on the execution of our lead clinical program, JTX-2011, and to continue to advance our earlier-stage targets emerging from our Translational Science Platform,” said Richard Murray, Ph.D., chief executive officer of Jounce Therapeutics. “We continue to execute on our goal of being a leading next-generation immunotherapy company, having recently announced the start of the Phase 2 portion, designed to evaluate preliminary efficacy, of our Phase 1/2 ICONIC study of JTX-2011 in patients with advanced solid tumors. The safety, PK and PD data from the Phase 1 portion of the study, launched last summer, will be presented at ASCO 2017, and we remain on track to disclose data from the Phase 2 preliminary efficacy evaluation by the end of the year.”

Back to news